Here, we could show that serum adiponectin was increased in NASH, regardless of HCC occurrence, and an adiponectin/FGF19 ratio paralleled serum C4 levels, indicating a potential synergistic effect in NASH-HCC (see Figure S2B, Supplementary Digital Content 1, http://links.lww.com/CTG/A212). Here, ADIPOQ is linked to metabolic dysfunction-associated steatohepatitis.